CRISM Therapeutics Corporation (LSE:CRTX) has secured £800,000 via a placing of new ordinary shares to propel its ChemoSeed drug-delivery platform into the next development phase. These funds will underwrite manufacturing and the establishment of a Phase 2 clinical trial targeting glioblastoma, with dosing of the first patients slated for early 2026. The successful raise underscores investor confidence in CRISM’s approach and paves the way for existing shareholders to join a planned retail offer.
About CRISM Therapeutics Corporation
CRISM Therapeutics is a UK-based biotech company focused on novel drug-delivery systems designed to improve treatment outcomes for solid tumors. Its lead candidate, ChemoSeed, is engineered to deliver chemotherapy directly to high-grade gliomas, overcoming the challenges posed by the blood–brain barrier.
Leave a Reply